A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
about
Recurrent Glioblastoma: Where we standFotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma.Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated patients with recurrent glioblastoma: a single-institution analysis.Efficacy and safety of second-line fotemustine in elderly patients with recurrent glioblastomaFotemustine: a third-generation nitrosourea for the treatment of recurrent malignant gliomas.The combination of carmustine wafers and fotemustine in recurrent glioblastoma patients: a monoinstitutional experienceGEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomas.MR-guided laser-induced thermal therapy (LITT) for recurrent glioblastomas.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiformeThe future of high-grade glioma: Where we are and where are we going.Inhibition of STAT3 reverses drug resistance acquired in temozolomide-resistant human glioma cells.A retrospective pooled analysis of response patterns and risk factors in recurrent malignant glioma patients receiving a nitrosourea-based chemotherapy.Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection.Standards of care for treatment of recurrent glioblastoma--are we there yet?Safety of second-line chemotherapy with non-conventional fotemustine schedule in recurrent high grade gliomas: a single institution experienceTreatment options for recurrent glioblastoma: pitfalls and future trends.Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).Survival effect of first- and second-line treatments for patients with primary glioblastoma: a cohort study from a prospective registry, 1997-2010.An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.Evolution of care for patients with relapsed glioblastoma.The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.State of the art and perspectives in the treatment of glioblastoma.Treating recurrent glioblastoma: an update.Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.Blood-brain barrier, cytotoxic chemotherapies and glioblastoma.Perspectives of Medical Specialists on Sharing Decisions in Cancer Care: A Qualitative Study Concerning Chemotherapy Decisions With Patients With Recurrent Glioblastoma.Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study.Lecture: fotemustine in brain tumors.Unmet needs in the treatment of glioblastoma.Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma: final report of a pilot study.
P2860
Q26765042-E296C533-0390-432F-9713-7325E38CFED5Q33382912-36EE9D5C-DAE7-4799-AC58-981FEA3AEB39Q33391296-BEFF0563-E792-4DCA-9B39-E8FFF18437BBQ33402044-8FFC0240-15A5-4557-AF50-B979537F31F8Q33406919-32A6563A-2F57-46AE-B791-605483A8125EQ33411366-C1981733-23B7-4C3D-94A1-4D107C06D84EQ33415187-74C7724A-3CE5-4B95-AC12-9F48976F1BB3Q33427367-BE3F4E76-457A-4DCE-B1F5-0A7CB7159AD0Q33625227-2ED8A496-7A2F-48F6-BFD4-9ADECBD657A3Q34226398-4428CDEC-06D0-4E2C-8A88-0F2D8A55F56EQ35027024-F02B8A6D-729C-43CE-A29E-6DA1F3869986Q35114090-60A9CDDC-EC05-4170-A924-5C3AB72D8541Q36142675-A669B6B3-9B1A-457B-B09B-338952FA5272Q36143344-26E1320C-9F00-40A6-8EF6-A46C62F2FDB2Q36367414-B33855B6-D15F-4D10-A900-CA1A7BB505C8Q36500401-81AA9D7A-86C4-44C4-A834-63E0F7B02FF6Q36935024-0C6E5FC1-912C-4B37-91B4-D56B051B70A5Q37483971-1C3372C4-EC15-4BF5-8009-91A750D98790Q37526275-2FAA092E-87F6-40FA-B116-6F80EF715E09Q37699429-521B5AD7-90B1-446E-93BF-3F75662FADD3Q37858468-4F869782-4126-410B-9691-713F181ACEFEQ37952240-2541D3B6-12A2-4726-A8AA-123A7E3E3DF8Q38205133-3B5A6961-A1C8-4EAE-8CF7-8E297FA91C50Q38209678-FEB5D909-D235-45FF-B16A-9F20227399ADQ38233067-3692AEB3-C88F-447D-A017-2E544FB1C05AQ38376610-1E9716C1-466A-4B6C-818D-AA48F0534057Q38720644-64D29DC3-DF08-49CC-B7B3-B46B48613DE5Q38867048-FC7EF69E-3F81-4A8B-94FB-29D1C3AA5374Q41450286-D003D17A-44D0-48AF-99FC-8ADCB8C324D7Q43246067-C486011B-D15F-4D1A-BD2F-B8A469C1E170Q48536975-40DB1AE9-F26A-46EC-9E05-7D6A2953BBA9Q48614301-E8F9BBB9-C2AD-4483-A176-8D74E6AEA00BQ55461270-BFE81CAD-2A27-45DB-A0C9-2A31BDE60D48
P2860
A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
A multi-institutional phase II ...... apy in recurrent glioblastoma.
@en
A multi-institutional phase II ...... apy in recurrent glioblastoma.
@nl
type
label
A multi-institutional phase II ...... apy in recurrent glioblastoma.
@en
A multi-institutional phase II ...... apy in recurrent glioblastoma.
@nl
prefLabel
A multi-institutional phase II ...... apy in recurrent glioblastoma.
@en
A multi-institutional phase II ...... apy in recurrent glioblastoma.
@nl
P2093
P1476
A multi-institutional phase II ...... apy in recurrent glioblastoma.
@en
P2093
Annarita Marsella
Franco Perrone
Giovanni Silvano
Ivan Lolli
Luca Cionini
Maria Grazia Fabrini
Valerio Scotti
P2860
P2888
P356
10.1007/S11060-008-9739-6
P577
2008-11-19T00:00:00Z